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phy; approximately 94% of accredited mam-
mography units were digital as of March 1, 
2014 [7]. How this transition to digital tech-
nology has affected screen-detected versus 
interval cancer rates is unclear. In particular, 
the extent to which tumor characteristics of 
screen-detected versus interval cancers dif-
fer by imaging modality has, to our knowl-
edge, not been studied in the United States. 
Using national Breast Cancer Surveillance 
Consortium (BCSC) data from 2000 to 
2006, Kerlikowske et al. [8] found no differ-
ences in distribution of cancer stage, tumor 
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C
ompared with screen-detected 
cancers, interval cancers are more 
likely to be large, poorly differen-
tiated, and estrogen-receptor nega-
tive and to have lymph node involvement [1]. 
Hence, interval cancers typically present with a 
worse prognosis than do screen-detected can-
cers. Most studies examining tumor character-
istics of screen-detected versus interval cancers 
have focused on women undergoing screening 
with film mammography [2–6].
In the United States, digital mammogra-
phy has rapidly replaced film mammogra-
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OBJECTIVE. The purpose of this study was to determine whether pathologic findings of 
screen-detected and interval cancers differ for digital versus film mammography.
MATERIALS AND METHODS. Breast Cancer Surveillance Consortium data from 
2003–2011 on 3,021,515 screening mammograms (40.3% digital, 59.7% film) of women 40–
89 years old were reviewed. Cancers were considered screen detected if diagnosed within 12 
months of an examination with positive findings and interval if diagnosed within 12 months 
of an examination with negative findings. Tumor characteristics for screen-detected and in-
terval cancers were compared for digital versus film mammography by use of logistic regres-
sion models to estimate the odds ratio and 95% CI with adjustment for age, race and ethnicity, 
hormone therapy use, screening interval, examination year, and registry. Generalized esti-
mating equations were used to account for correlation within facilities.
RESULTS. Among 15,729 breast cancers, 85.3% were screen detected and 14.7% were in-
terval. Digital and film mammography had similar rates of screen-detected (4.47 vs 4.42 per 
1000 examinations) and interval (0.73 vs 0.79 per 1000 examinations) cancers for digital ver-
sus film. In adjusted analyses, interval cancers diagnosed after digital examinations with neg-
ative findings were less likely to be American Joint Committee on Cancer stage IIB or higher 
(odds ratio, 0.69; 95% CI, 0.52–0.93), have positive nodal status (odds ratio, 0.78; 95% CI, 
0.64–0.95), or be estrogen receptor negative (odds ratio, 0.71; 95% CI, 0.56–0.91) than were 
interval cancers diagnosed after a film examination with negative findings.
CONCLUSION. Screen-detected cancers diagnosed after digital and film mammog-
raphy had similar rates of unfavorable tumor characteristics. Interval-detected cancers di-
agnosed after a digital examination were less likely to have unfavorable tumor features than 
those diagnosed after film mammography, but the absolute differences were small.
Henderson et al.
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size, nodal status, or tumor grade for digital 
versus film, but the analysis was not strati-
fied by screen-detected versus interval can-
cer. The investigators did report that digital 
mammography had a higher sensitivity in the 
detection of estrogen receptor–negative tu-
mors than did film-screen mammography. A 
2014 study from The Netherlands [9] exam-
ined the pathologic findings of interval can-
cers for digital versus film mammography. 
The study showed that the tumor characteris-
tics were comparable, but it is unclear wheth-
er similar patterns exist in the United States.
The purpose of our study was to examine 
and compare tumor characteristics of screen-
detected and interval cancers by imaging 
modality (digital versus film) among wom-
en undergoing community-based mammo-
graphic screening in the United States.
Materials and Methods
Data Sources
The data for this study were collected from six 
registries that participate in the BCSC: Carolina 
Mammography Registry, Group Health Coopera-
tive (Washington State), New Hampshire Mam-
mography Network, New Mexico Mammography 
Project, San Francisco Mammography Regis-
try, and the Vermont Breast Cancer Surveillance 
System [10]. The prospective data collected from 
participating BCSC mammography practices in-
clude patient self-reported demographic charac-
teristics, indication for breast imaging visit, breast 
cancer risk factors, mammographic assessment, 
and management recommendations. These data 
are linked with tumor information from pathol-
ogy databases and regional cancer registry data. 
Each registry site submits data to a statistical co-
ordinating center for quality control checks and 
pooled analyses. Each registry and the statistical 
coordinating center received institutional review 
board approval for either active or passive consent 
or a waiver of consent to enroll participants, link 
study data, and perform analytic studies. All pro-
cedures were HIPAA compliant, and all registries 
received a federal certificate of confidentiality.
Study Population
We included mammograms of women 40–89 
years old obtained from 2003 to 2011 for which 
the indication was screening as noted by the radi-
ologist or technologist [11]. We excluded mam-
mograms of women with a previous breast cancer 
diagnosis, mastectomy, or implants. We also ex-
cluded data from eight Fuji Computed Radiogra-
phy Mammography Suite machines (3.9% of the 
data) because the sensitivity of computed radiog-
raphy is lower than that of digital direct radiogra-
phy and because almost all digital mammography 
machines in current use are digital direct radiog-
raphy systems. To avoid misclassifying diagnostic 
examinations as screening, we excluded examina-
tions of patients who had undergone mammogra-
phy or breast ultrasound in the previous 9 months 
or in which only unilateral mages were obtained. 
The final study examinations included 3,021,515 
screening mammograms, of which 1,218,314 
(40.3%) were digital examinations and 1,803,201 
(59.7%) were film examinations.
Definitions
Women were considered to have incident breast 
cancer if a diagnosis of invasive carcinoma or duc-
tal carcinoma in situ (DCIS) was made within 12 
months of the screening mammogram and be-
fore the next screening mammogram [12]. Inva-
sive cancers were further categorized according 
to American Joint Committee on Cancer (AJCC), 
sixth edition, stage; Surveillance Epidemiology 
End Result (SEER) summary stage; grade; tumor 
size at the time of pathologic examination; lymph 
node status; and hormone receptor status.
Each screening mammographic interpretation 
was classified as positive or negative on the basis 
of radiologists’ BI-RADS screening assessments. 
We defined a positive interpretation as BI-RADS 
category 0 (additional imaging required), 4 (needs 
evaluation), or 5 (highly suggestive of malignan-
cy) or as BI-RADS 3 (probably benign) when the 
recommendation was for immediate workup. We 
defined a negative interpretation as BI-RADS 
category 1 (negative) or 2 (benign finding) or as 
BI-RADS 3 (probably benign) with no recom-
mendation for immediate additional imaging [13, 
14]. We categorized the BI-RADS 3 assessments 
in this manner to account for the differences in 
how some practicing radiologists use BI-RADS 
category 3 with additional imaging recommend-
ed instead of using BI-RADS category 0 [13, 15]. 
We defined screen-detected cancers as those diag-
nosed within 12 months of a screening mammo-
graphic examination with a positive finding and 
before the next screening examination. We de-
fined interval cancers as those diagnosed within 
12 months of a negative screening mammographic 
result and before the next screening examination.
Statistical Analyses
We examined the distribution of patient char-
acteristics and compared the tumor characteristics 
of screen-detected versus interval cancers by im-
aging modality. To obtain estimates of the odds 
ratios (ORs) of the presence of favorable and un-
favorable tumor characteristics for digital versus 
film by mode of detection, we fit two separate lo-
gistic regression models. We accounted for cor-
relation within facilities by using generalized es-
timating equations. We separately modeled the 
rates of cancers with favorable and unfavorable 
tumor characteristics among all women, regard-
less of cancer status. We adjusted the models for 
age, race and ethnicity, current hormone therapy 
use, time since last mammogram (i.e., the mam-
mogram before the one used in this study), exami-
nation year, and registry site. We excluded exami-
nations with unknown covariates from the logistic 
regression models. All analyses were performed 
with SAS software (version 9.2, SAS Institute).
Results
Patient Characteristics for 
Screening Mammograms
The digital (n = 1,218,314) and film (n = 
1,803,201) examination groups had simi-
lar distributions of age, family history of 
breast cancer, menopausal status, history of 
breast biopsy, BI-RADS breast density, and 
BI-RADS category (Table 1). Asian patients 
were more likely to undergo digital mam-
mography, and Hispanic patients were more 
likely to undergo film mammography. There 
was less hormone therapy use among women 
undergoing digital mammography. Women 
undergoing digital examinations were more 
likely to have undergone mammography 
within the previous year than were women 
undergoing film examinations (69% versus 
61%). The uptake of digital mammography 
is evident from the distribution of examina-
tion years by imaging modality during the 
study period. Similar proportions of digital 
and film examinations resulted in screen-de-
tected (0.44% for both) and interval cancers 
(0.073% and 0.079%) for both modalities.
Patient Characteristics of Screen-Detected and 
Interval Cancers
A total of 15,729 breast cancers were di-
agnosed in the 12 months of follow-up after 
the screening mammographic examination 
and before the next one; 85.3% (n = 13,418) 
of these cancers were screen detected and 
14.7% (n = 2311) were interval cancers. Of 
the screen-detected cancers, 5441 (40.6%) 
were in the digital and 7977 (59.4%) were in 
the film examination group (Table 2). For in-
terval cancers, 895 (38.7%) were in the digi-
tal and 1416 (61.3%) were in the film exami-
nation group. Compared with screen-detected 
cancers and regardless of imaging modality, 
interval cancers were found in higher propor-
tion among younger women, premenopaus-
al or perimenopausal women, women with a 
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breasts, and women who had undergone 
screening in the previous 12 months.
Tumor Characteristics of Screen-Detected and 
Interval Cancers
The screen-detected cancer rates per 
1000 examinations were similar for digital 
and film mammography (4.47 and 4.42), as 
was the interval cancer rate (0.73 and 0.79 
per 1000 examinations) (Table 3). Interval 
cancers were more likely to have unfavor-
able tumor characteristics regardless of im-
aging modality. Specifically, interval can-
cers were more likely to be invasive, stage 
IIB or higher; be in a SEER summary re-
gional or distant stage; be larger than 20 
mm; have positive nodal status; be grade 
III; and be estrogen or progesterone recep-
tor negative. Screen-detected cancers iden-
tified with digital mammography were more 
likely to be DCIS than were those detected 
TABLE 1: Characteristics of Patients Undergoing Screening Mammographic Examinations
Characteristic
Digital Mammography Film Mammography
N % N %
No. of examinations 1,218,314 100.0 1,803,201 100.0
No. of women 528,786 100.0 860,769 100.0
Age at examination (y)
40–49 353,576 29.0 506,225 28.1
50–59 386,670 31.7 582,199 32.3
60–69 279,405 22.9 395,008 21.9
70–79 148,007 12.1 240,072 13.3
≥ 80 50,656 4.2 79,697 4.4
Race, ethnicity
White, non-Hispanic 798,587 70.8 1,272,476 75.1
Black, non-Hispanic 73,942 6.6 103,795 6.1
Asian, Native Hawaiian, Pacific Islander 184,321 16.3 116,206 6.9
American Indian, Alaska Native 3230 0.3 15,721 0.9
Hispanic 48,165 4.3 159,092 9.4
Other 19,106 1.7 28,204 1.7
Family history of breast cancer
Yes 185,669 15.5 265,202 15.4
No 1,011,827 84.8 1,451,897 84.6
Menopausal status
Premenopausal or perimenopausal 300,255 28.3 397,577 25.6
Postmenopausal 759,995 71.7 1,154,689 74.4
Current hormone therapy use
Yes 96,971 9.1 227,229 14.3
No 965,832 90.9 1,358,359 85.7
History of breast biopsy
Yes 239,255 20.6 350,516 20.3
No 924,618 79.4 1,379,133 79.7
BI-RADS breast density
Almost entirely fat 119,259 11.6 125,314 9.1
Scattered fibroglandular densities 437,719 42.7 633,987 45.9
Heterogeneously dense 392,365 38.3 513,928 37.2
Extremely dense 74,597 7.3 106,800 7.7
Time since previous mammogram
No previous 35,628 3.1 53,231 3.2
1 y (9–18 mo) 803,566 69.1 1,032,147 61.2
2 y (19–30 mo) 192,012 16.5 372,001 22.1
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≥ 3 y (≥ 31 mo) 130,920 11.3 228,519 13.6
Examination year
2003 33,434 2.7 405,357 22.5
2004 42,833 3.5 383,756 21.3
2005 52,876 4.3 340,721 18.9
2006 101,393 8.3 249,973 13.9
2007 175,943 14.4 183,751 10.2
2008 209,883 17.2 119,620 6.6
2009 256,168 21.0 70,476 3.9
2010 256,176 21.0 38,910 2.2
2011 89,608 7.4 10,637 0.6
BI-RADS category
0, Incomplete assessment 126,018 10.3 165,758 9.2
1, Negative 791,227 64.9 1,142,978 63.4
2, Benign finding 297,560 24.4 482,449 26.8
3, Probably benign 2513 0.2 9,346 0.5
4, Suspicious abnormality 912 0.1 2,274 0.1
5, Highly suggestive of malignancy 84 0 396 0
Outcome
Screen-detected cancer 5441 0.4 7977 0.4
Interval cancer 895 0.1 1416 0.1
No cancer 1,211,978 99.5 1,793,808 99.5
Note—Counts for certain characteristics do not total to N owing to missing data.
TABLE 1: Characteristics of Patients Undergoing Screening Mammographic Examinations (continued)
Characteristic
Digital Mammography Film Mammography
N % N %
TABLE 2: Characteristics of Women With Screen-Detected and Interval Cancers by Imaging Modality: Breast Cancer 
Surveillance Consortium 2003–2011
Characteristic
Screen-Detected Cancer (n = 13,418) Interval Cancer (n = 2311)
Digital Film Digital Film
N % N % N % N %
No. of womena 5441 40.6 7977 59.4 895 38.7 1416 61.3
Age at examination (y)
40–49 1004 18.5 1277 16.0 225 25.1 347 24.5
50–59 1502 27.6 2357 29.5 263 29.4 410 29.0
60–69 1537 28.2 2134 26.8 223 24.9 365 25.8
70–79 1010 18.6 1573 19.7 131 14.6 227 16.0
≥ 80 388 7.1 636 8.0 53 5.9 67 4.7
Race, ethnicity
White, non-Hispanic 3736 73.9 5914 77.9 642 76.2 1077 80.3
Black, non-Hispanic 324 6.4 450 5.9 54 6.4 81 6.0
Asian, Native Hawaiian, Pacific Islander 720 14.2 483 6.4 111 13.2 73 5.4
American Indian, Alaska Native 10 0.2 57 0.8 4 0.5 14 1.0
Hispanic 92 1.8 151 2.0 14 1.7 20 1.5
Other 174 3.4 532 7.0 18 2.1 76 5.7
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Family history of breast cancer
Yes 1209 22.6 1645 21.7 218 24.7 322 23.5
No 4130 77.4 5937 78.3 666 75.3 1049 76.5
Menopausal status
Premenopausal or perimenopausal 987 19.7 1243 17.1 229 28.4 322 25.6
Postmenopausal 4019 80.3 6046 82.9 578 71.6 934 74.4
Current hormone therapy use
Yes 503 10.7 996 14.7 95 12.6 227 18.1
No 4195 89.3 5764 85.3 659 87.4 1028 81.9
History of breast biopsy
Yes 1438 27.7 2166 28.1 288 35.2 464 33.8
No 3762 72.2 5539 71.9 530 64.8 908 66.2
BI-RADS breast density
Almost entirely fat 356 8.2 325 5.7 34 4.5 37 3.4
Scattered fibroglandular densities 1918 44.2 2571 45.0 236 31.5 359 33.3
Heterogeneously dense 1800 41.5 2448 42.8 386 51.5 533 49.4
Extremely dense 264 6.1 372 6.5 93 12.4 150 13.9
Time since previous mammogram
No previous 197 3.8 329 4.5 21 2.4 24 1.8
1 y (9–18 mo) 3021 58.9 3663 49.7 624 72.7 892 66.0
2 y (19–30 mo) 928 18.1 1804 24.5 120 14.0 280 20.7
≥ 3 y (≥ 31 mo) 982 19.1 1567 21.3 93 10.8 155 11.5
a Percentages are for the row by screen-detected and interval cancer groups. All other percentages are column percentages.
TABLE 2: Characteristics of Women With Screen-Detected and Interval Cancers by Imaging Modality: Breast Cancer 
Surveillance Consortium 2003–2011 (continued)
Characteristic
Screen-Detected Cancer (n = 13,418) Interval Cancer (n = 2311)
Digital Film Digital Film
N % N % N % N %
TABLE 3: Rates of Cancer per 1000 Mammograms by Tumor Characteristics, Mode of Detection, and Imaging 
 Modality: Breast Cancer Surveillance Consortium 2003–2011
Cancer Characteristic
Screen-Detected Cancer (n = 13,418) Interval Cancer (n = 2311)

























Totala 5441 86 4.47 7977 85 4.42 895 14 0.73 1416 15 0.79
DCIS 1638 30 1.34 1854 23 1.03 106 12 0.09 132 9 0.07
Invasive 3803 70 3.12 6123 77 3.40 789 88 0.65 1284 91 0.71
American Joint Committee on Cancer stage
I 2313 63 1.90 3530 61 1.96 311 41 0.26 466 39 0.26
IIA 780 21 0.64 1200 21 0.67 229 30 0.19 338 28 0.19
IIB 334 9 0.27 552 10 0.31 103 14 0.08 162 13 0.09
III 211 6 0.17 393 7 0.22 97 13 0.08 187 16 0.10
IV 34 1 0.03 67 1 0.04 21 3 0.02 48 4 0.03
Unknown 131 3 0.11 381 6 0.21 28 4 0.02 83 6 0.05
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with film mammography (1.34 vs 1.03 per 
1000 examinations). Yet there was little dif-
ference in invasive tumor features for digi-
tal or film screen-detected cancers. Interval 
cancers diagnosed after digital mammog-
raphy were also slightly more likely to be 
DCIS but with few differences in invasive 
tumor features.
Relative Risk of Unfavorable 
Tumor Characteristics
The adjusted ORs of having unfavorable 
tumor characteristics were significantly dif-
Surveillance, Epidemiology, and End 
Results summary stage
Local 2868 78 2.35 4433 76 2.46 492 64 0.40 723 59 0.40
Regional 776 21 0.64 1362 23 0.76 252 33 0.21 459 37 0.25
Distant 36 1 0.03 68 1 0.04 23 3 0.02 49 4 0.03
Unknown 123 3 0.10 260 4 0.14 22 3 0.02 53 4 0.03
Tumor size (mm)
≤ 10 1184 34 0.97 1778 32 0.99 124 17 0.10 193 16 0.11
11–20 1410 40 1.16 2266 41 1.26 269 36 0.22 431 37 0.24
> 20 903 26 0.74 1536 28 0.85 346 47 0.28 548 47 0.30
Unknown 306 8 0.25 543 9 0.30 50 6 0.04 112 9 0.06
Nodal status
Negative 2917 78 2.39 4534 76 2.51 504 65 0.41 757 61 0.42
Positive 812 22 0.67 1425 24 0.79 270 35 0.22 493 39 0.27
Unknown 74 2 0.06 164 3 0.09 15 2 0.01 34 3 0.02
Grade
1 1142 32 0.94 1635 29 0.91 153 21 0.13 235 21 0.13
2 1597 45 1.31 2436 44 1.35 313 43 0.26 455 40 0.25
3 838 23 0.69 1512 27 0.84 269 37 0.22 447 39 0.25
Unknown 226 6 0.19 540 9 0.30 54 7 0.04 147 11 0.08
Estrogen receptor status
Positive 3137 87 2.57 4630 85 2.57 589 79 0.48 836 74 0.46
Negative 468 13 0.38 807 15 0.45 161 21 0.13 294 26 0.16
Unknown 198 5 0.16 686 11 0.38 39 5 0.03 154 12 0.09
Progesterone receptor status
Positive 2798 78 2.30 4022 75 2.23 521 70 0.43 733 65 0.41
Negative 804 22 0.66 1373 25 0.76 227 30 0.19 393 35 0.22
Unknown 201 5 0.16 728 12 0.40 41 5 0.03 158 12 0.09
ERBB2b
Positive 316 12 0.26 549 15 0.30 76 14 0.06 125 18 0.07
Negative 2243 88 1.84 2995 85 1.66 478 86 0.39 574 82 0.32
Unknown 1244 33 1.02 2579 42 1.43 235 30 0.19 585 46 0.32
Triple negative
Yes 210 8 0.17 287 8 0.17 78 14 0.06 103 15 0.06
No 2333 92 1.91 3148 92 1.91 473 86 0.39 578 85 0.32
Unknown 1260 33 1.03 2688 44 1.03 238 30 0.20 603 47 0.33
aPercentages are for the row. All other percentages are column percentages.
bAlso known as known as HER2 or HER2/neu.
TABLE 3: Rates of Cancer per 1000 Mammograms by Tumor Characteristics, Mode of Detection, and Imaging 
 Modality: Breast Cancer Surveillance Consortium 2003–2011 (continued)
Cancer Characteristic
Screen-Detected Cancer (n = 13,418) Interval Cancer (n = 2311)
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ferent for digital versus film mammography 
among women with interval cancers but not 
among women with screen-detected cancers 
(Table 4). For women with interval cancers, 
cancers diagnosed after digital mammog-
raphy were slightly less likely to have un-
favorable tumor features than were cancers 
diagnosed after film mammography. For 
example, interval cancers not seen on digi-
tal mammograms were 31% less likely than 
interval cancers not seen on film mammo-
grams to present at AJCC stage IIB or higher 
(adjusted OR, 0.69; 95% CI, 0.52–0.93; rate, 
0.12 vs 0.18 per 1000 examinations), 22% 
less likely to be regional or distant disease 
(adjusted OR, 0.78; 95% CI, 0.64–0.95; rate 
0.23 vs 0.28 per 1000 examinations), 22% 
less likely to have positive nodal status (ad-
justed OR, 0.78; 95% CI, 0.64–0.95; rate, 
0.22 vs 0.27 per 1000 examinations), and 
29% less likely to present with estrogen re-
ceptor–negative tumors (adjusted OR, 0.71; 
95% CI, 0.56–0.91; rate, 0.13 vs 0.16 per 
1000 examinations).
In contrast, the adjusted ORs of having fa-
vorable tumor characteristics (early stage, 
smaller tumor size, negative nodal status, 
lower grade, and estrogen receptor–positive 
tumors) were not significantly different for 
digital versus film mammography for screen-
detected or interval cancers. The one excep-
tion was among screen-detected cancers, in 
which the adjusted OR of having DCIS versus 
invasive disease was 1.30 (95% CI, 1.15–1.48), 
indicating that DCIS is more frequently de-
tected on digital than on film mammograms.
Discussion
Our findings revealed a similar proportion 
of interval cancers among women screened 
with digital mammography and those 
screened with film mammography. This pro-
portion is similar to the 13.8% reported in 
the Ontario Breast Screening Program [1]. 
We also found that the rates of screen-detect-
ed and interval cancers were similar across 
modalities. Our rates are substantially lower 
than those found in a 2014 study conducted 
in The Netherlands by Nederend et al. [9], 
who reported an interval cancer rate for dig-
ital mammography of 2.0 per 1000 exami-
nations versus 1.7 per 100 for film mammo-
grams. Hoff et al. [16] reported similar rates 
of screen-detected invasive cancer and inter-
val cancer but higher rates of screen-detected 
DCIS on digital than on film mammograms. 
Studies from Ireland, The Netherlands, and 
Norway [17–19] showed increased can-
cer detection rates with digital mammogra-
phy, whereas studies from Spain, the United 
Kingdom, and the United States showed sim-
ilar cancer detection rates for digital and film 
mammography [2, 8, 17–21].
As in previous studies based on film mam-
mography [22–24], we found that interval 
cancers were more likely than screen-detect-
ed cancers to have unfavorable tumor char-
acteristics. In particular, interval cancers 
had a higher stage, larger size, and greater 
frequencies of positive lymph node involve-
ment and estrogen receptor–negative status. 
Our results also agree with those of a study 
TABLE 4: Odds Ratios of Having Tumor Characteristics With Worse Prognosis (Relative to Better Prognosis or 
No Cancer) and Better Prognosis (Relative to Worse Prognosis or No Cancer) for Digital Versus Film 
 Mammography: Breast Cancer Surveillance Consortium 2003–2011
Cancer Characteristic
Screen-Detected Cancers Interval Cancers
Unadjusted Odds Ratio Adjusted Odds Ratioa Unadjusted Odds Ratio Adjusted Odds Ratioa
All
Cancer diagnosis 1.01 (0.94–1.09) 1.06 (0.97–1.16) 0.94 (0.81–1.08) 0.93 (0.78–1.10)
Unfavorable prognosis
Invasive cancers 0.92 (0.85–0.90) 0.98 (0.89–1.07) 0.91 (0.79–1.04) 0.90 (0.77–1.06)
AJCC stage IIB or higher 0.85 (0.70–1.02) 1.02 (0.85–1.23) 0.82 (0.68–1.01) 0.69 (0.52–0.93)
Regional or distant SEER summary stageb 0.84 (0.74–0.95) 1.07 (0.93–1.24) 0.80 (0.68–0.94) 0.78 (0.64–0.95)
Tumor size > 20 mm 0.87 (0.76–1.00) 0.96 (0.81–1.14) 0.94 (0.78–1.13) 0.83 (0.66–1.04)
Positive nodal status 0.84 (0.75–0.95) 1.07 (0.93–1.24) 0.81 (0.69–0.95) 0.78 (0.64–0.95)
Grade 3 0.82 (0.73–0.92) 0.99 (0.85–1.15) 0.89 (0.72–1.09) 0.84 (0.67–1.06)
Estrogen receptor negative 0.86 (0.73–1.00) 0.96 (0.78–1.18) 0.81 (0.64–1.03) 0.71 (0.56–0.91)
Favorable prognosis
DCIS 1.31 (1.17–1.46) 1.30 (1.15–1.48) 1.19 (0.88–1.60) 1.19 (0.71–1.98)c
AJCC stage IIA or earlier 0.97 (0.88–1.06) 0.99 (0.90–1.09) 0.99 (0.86–1.15) 1.03 (0.85–1.24)
Local SEER summary stagec 0.96 (0.88–1.04) 0.95 (0.87–1.05) 1.01 (0.86–1.18) 0.99 (0.80–1.24)
Tumor size ≤ 20 mm 0.95 (0.86–1.05) 1.00 (0.90–1.11) 0.93 (0.79–1.09) 0.97 (0.80–1.19)
Negative nodal status 0.95 (0.88–1.03) 0.96 (0.87–1.05) 0.99 (0.84–1.16) 0.97 (0.78–1.21)
Grade I or II 1.00 (0.91–1.09) 1.01 (0.90–1.12) 1.00 (0.84–1.19) 1.01 (0.83–1.24)
Estrogen receptor positive 1.00 (0.91–1.10) 0.97 (0.88–1.07) 1.04 (0.90–1.21) 0.98 (0.81–1.18)
Note—Values in parentheses are 95% CI. Bold type indicates statistically significant value. AJCC = American Joint Committee on Cancer, SEER = Surveillance, 
 Epidemiology, and End Results, DCIS = ductal carcinoma in situ.
aAdjusted for current hormone therapy use, age, race and ethnicity, screening interval, examination year, and Breast Cancer Surveillance Consortium registry.
bSEER summary stages are local, regional, and distant.
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conducted with data from the Dutch Micro-
array in Node-Negative Disease May Avoid 
Chemotherapy trial. That study [25] showed 
that tumor characteristics of cancers screen 
detected with digital mammography were 
similar to those of cancers detected with film 
mammography and that interval cancers di-
agnosed after screening with film mammog-
raphy had more unfavorable characteristics 
than cancers diagnosed after digital mam-
mography. We add to the existing literature 
in that previous work focused on screen-
detected and interval cancers based on film 
mammographic findings and our study in-
cludes more than 3800 cancers diagnosed af-
ter digital mammography.
Among women with interval cancer, ad-
justed ORs of unfavorable tumor characteris-
tics were lower for digital than for film mam-
mography. This finding was not observed for 
screen-detected cancers. A 2014 study con-
ducted in The Netherlands [9] compared 
characteristics of interval cancers among 
63,182 women screened with digital mam-
mography and 60,770 women screened with 
film mammography between 2008 and 2010. 
That study did not show differences in breast 
density, tumor size, lymph node status, or 
hormone receptor status between digital- 
and film-detected interval cancers. It is pos-
sible that the difference between the film ver-
sus digital interval cancers we observed and 
the findings of Nederend et al. [9] reflects the 
different interval cancer rates in The Nether-
lands and the United States or that Nederend 
et al. defined interval cancers on the basis of 
2 years of follow-up.
In our study we found almost identical 
overall cancer detection rates of 5.20 and 
5.21 per 1000 examinations for digital and 
film mammography. Interestingly, digital 
mammography showed more instances of 
DCIS. The meaning of this finding is un-
clear, but one possibility is that the types of 
DCIS found at digital mammography may 
lead to fewer interval cancers with poor 
prognostic characteristics. We do not believe 
this is the case because mammographically 
detected DCIS has a less than 10% chance 
of being associated with a subsequent inva-
sive cancer in 10 years, and most subsequent 
invasive cancers are not as aggressive as the 
interval cancers in our study [25]. This un-
explained and interesting finding deserves 
more study.
The strengths of our study include the 
ability to examine both digital and film 
mammograms in a national cohort of screen-
ing mammograms from community-based 
practices. The BCSC dataset contains a large 
number of screen-detected and interval can-
cers even after stratification by imaging mo-
dality. Our study also had limitations, how-
ever. First, in the BCSC data, we were unable 
to determine whether the interval cancers 
were true interval cancers or missed cancers 
that were visible on the screening images. 
Second, we had incomplete data on ERBB2 
status (also known as HER2 or HER2/neu), 
another important prognostic factor. Be-
cause the SEER data more comprehensively 
capture ERBB2 status, the lack of data re-
mains a problem for many studies conducted 
with state cancer registries.
Our study results suggest that the transi-
tion to digital mammography in the United 
States has not reduced the interval cancer 
rate. Interval cancers constitute approxi-
mately 15% of breast cancers for both digi-
tal and film mammography. However, inter-
val cancers detected after negative results of 
a digital examination had a lower rate of un-
favorable characteristics than those detected 
after negative results of a film examination, 
which may improve treatment outcomes. The 
pathologic findings are similar for screen-de-
tected cancers whether the modality is digi-
tal or film. As technologies in breast imaging 
change in the future, a study similar to this 
one that compares the pathologic features of 
cancers detected with digital mammography 
with those of cancers detected with tomosyn-
thesis will be important to determine wheth-
er screen-detected and interval cancers vary 
in a clinically meaningful way between these 
two modalities.
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